Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Mar 1;10(3):63.
doi: 10.3390/cancers10030063.

Kinases and Cancer

Jonas Cicenas  1   2   3 , Egle Zalyte  4 , Amos Bairoch  5   6 , Pascale Gaudet  7
Affiliations
Editorial

Kinases and Cancer

Jonas Cicenas et al. Cancers (Basel). .

Abstract

Protein kinases are a large family of enzymes catalyzing protein phosphorylation. The human genome contains 518 protein kinase genes, 478 of which belong to the classical protein kinase family and 40 are atypical protein kinases [...].

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The neXtProt function page for MAPK13 (https://www.nextprot.org/entry/NX_O15264/).
Figure 2
Figure 2
Imatinib (Gleevec) is the first FDA approved kinase inhibitor. Approved for the treatment of KIT+ GIST and Ph+ CML.
See this image and copyright information in PMC

References

    1. Hunter T., Cooper J.A. Protein-tyrosine kinases. Annu. Rev. Biochem. 1985;54:897–930. doi: 10.1146/annurev.bi.54.070185.004341. - DOI - PubMed
    1. Gaudet P., Michel P.A., Zahn-Zabal M., Britan A., Cusin I., Domagalski M., Duek P.D., Gateau A., Gleizes A., Hinard V., et al. The nextprot knowledgebase on human proteins: 2017 update. Nucleic Acids Res. 2017;45:D177–D182. doi: 10.1093/nar/gkw1062. - DOI - PMC - PubMed
    1. Nukaga S., Yasuda H., Tsuchihara K., Hamamoto J., Masuzawa K., Kawada I., Naoki K., Matsumoto S., Mimaki S., Ikemura S., et al. Amplification of egfr wild-type alleles in non-small cell lung cancer cells confers acquired resistance to mutation-selective egfr tyrosine kinase inhibitors. Cancer Res. 2017;77:2078–2089. doi: 10.1158/0008-5472.CAN-16-2359. - DOI - PubMed
    1. Khan S.A., Zeng Z., Shia J., Paty P.B. Egfr gene amplification and kras mutation predict response to combination targeted therapy in metastatic colorectal cancer. Pathol. Oncol. Res. 2017;23:673–677. doi: 10.1007/s12253-016-0166-2. - DOI - PMC - PubMed
    1. Chang N., Lee H.W., Lim J.E., Jeong D.E., Song H.J., Kim S., Nam D.H., Sung H.H., Jeong B.C., Seo S.I., et al. Establishment and antitumor effects of dasatinib and pki-587 in bd-138t, a patient-derived muscle invasive bladder cancer preclinical platform with concomitant egfr amplification and pten deletion. Oncotarget. 2016;7:51626–51639. doi: 10.18632/oncotarget.10539. - DOI - PMC - PubMed

Publication types